Repligen Corporation Announces Agreement to Acquire Polymem S.A.
June 22, 2021 06:30 ET
|
Repligen Corporation
WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into...
Repligen Corporation to Present at Upcoming Investor Conferences
May 25, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
May 04, 2021 07:30 ET
|
Repligen Corporation
Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69%Growth driven by combination of COVID-related demand, base business strength and...
Repligen to Report First Quarter 2021 Financial Results
April 20, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021....
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
March 17, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Corporation to Present at Barclays Global Healthcare Conference
March 03, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021 07:30 ET
|
Repligen Corporation
Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the...
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
February 22, 2021 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present...
Repligen to Report Fourth Quarter and Full Year 2020 Financial Results
February 11, 2021 15:00 ET
|
Repligen Corporation
Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. ESTWALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the...
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines
February 08, 2021 07:36 ET
|
Repligen Corporation
WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo...